Ozempic & GLP-1 Lawsuit in North Dakota

GLP-1 receptor agonist medications — including Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, and Trulicity — were prescribed to millions of North Dakota residents for type 2 diabetes and weight management. While these drugs were marketed as breakthrough treatments, growing evidence has linked them to severe and sometimes permanent injuries that the manufacturers allegedly failed to adequately disclose.

The federal litigation against Novo Nordisk and Eli Lilly has been consolidated into multidistrict litigation (MDL 3094) in the Eastern District of Pennsylvania. North Dakota residents who suffered injuries from GLP-1 medications can file claims that join this consolidated proceeding, benefiting from coordinated pretrial discovery while retaining their individual right to trial.

The lawsuits allege that the manufacturers knew their drugs could cause serious gastrointestinal injuries — including stomach paralysis, bowel blockages, and pancreatic inflammation — as well as vision loss, yet they prioritized profits over patient safety by failing to warn prescribers and patients about the true scope of these risks. For North Dakota residents, the stakes are high: these injuries can be permanent, require multiple surgeries, and fundamentally alter quality of life.

As the litigation progresses, early bellwether trials are expected to set the stage for broader settlement discussions. North Dakota residents who have been injured should evaluate their claims now, before filing deadlines expire.

North Dakota legal landscape: North Dakota applies modified comparative fault with a 50% bar and follows strict liability for defective products. The state does not impose statutory caps on compensatory damages, but punitive damages require proof of oppression, fraud, or malice by clear and convincing evidence. Residents in Fargo, Bismarck, and Grand Forks and surrounding areas should consult with an attorney experienced in pharmaceutical litigation to evaluate their potential claim.